Topic Name

Message

If ARUP Consult does not answer your test selection and interpretation questions, or if you would like to suggest ways to improve content or usability, please send a message to the Consult editorial staff.

Please do not include any patient-specific or personal health information (PHI) in your message.

Email Address

An email address is not required, but providing one allows the ARUP Consult editorial staff to respond directly. ARUP will only use your email address to respond to your feedback. See the ARUP privacy policy for more information regarding email use.

CAPTCHA

What code is in the image?

Enter the characters shown in the image.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

UGT1A1 Genotype-Guided Chemotherapy

0051332

UDP Glucuronosyltransferase 1A1 (UGT1A1) Genotyping 0051332

About This Topic

Genetic polymorphisms in UGT1A1, which encodes for the uridine diphosphate glucuronosyltransferase (UGT)1A1 enzyme, may influence drug-induced toxicities of numerous medications used in oncology, especially irinotecan chemotherapy. Hospitalization risk from chemotherapy-induced neutropenia and diarrhea is heightened in people carrying genotypes predicted to be UGT1A1 poor metabolizers (PMs).

Recommendation

Guide chemotherapy drug and dose selection by UGT1A1 genotyping (0051332) to reduce hospitalization risk from severe neutropenia and diarrhea.

ARUP Consult

ARUP Test Fact Sheet

CPIC Guideline for Atazanavir and UGT1A1

Clinical Pharmacogenetics Implementation Consortium. CPIC guideline for atazanavir and UGT1A1. Updated Nov 2017; accessed Jul 2022.

Feedback

UGT1A1 Genotype-Guided Chemotherapy

CPIC Guideline for Atazanavir and UGT1A1